Endometrial Cancer Clinical Trials in Dessau
2 recruitingDessau, Germany
Showing 1–2 of 2 trials
Recruiting
Phase 3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
AstraZeneca600 enrolled249 locationsNCT06989112
Recruiting
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
Endometrial Cancer
AstraZeneca150 enrolled33 locationsNCT06890273